MARIAM BERBERIAN: Open Payments
NPI 1447638234 · BURBANK, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,606 in 27 payments from 8 companies in 2025. Trend: 2023 $706 · 2024 $1,262 · 2025 $1,606
Food & beverage: $1,494Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 6 | $441 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $388 |
| E.R. Squibb & Sons, L.L.C. | 4 | $242 |
| Axsome Therapeutics, Inc. | 4 | $179 |
| Vanda Pharmaceuticals Inc. | 2 | $132 |
| Otsuka America Pharmaceutical, Inc. | 4 | $113 |
| Janssen Pharmaceuticals, Inc | 3 | $82 |
| GlaxoSmithKline, LLC. | 1 | $29 |
Products named: CAPLYTA, COBENFY, AUSTEDO XR, Auvelity, UZEDY, REXULTI, FANAPT, SPRAVATO.
Industry payments across CA — which companies pay providers there.
